Kevin G. Pollock

Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study

Kimberley Kavanagh, Kevin G. Pollock, Kate Cuschieri et al. · The Lancet Infectious Diseases · 2017 · 258 citations · Full text

Vaccination, Cervical Health, Human Papillomavirus Vaccines +7

Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland

Kevin G. Pollock, Kimberley Kavanagh, A Potts et al. · British Journal of Cancer · 2014 · 159 citations · Full text

Analysis of the role of vaccine adjuvants in modulating dendritic cell activation and antigen presentation in vitro

Hongfan Sun, Kevin G. Pollock, James M. Brewer · Vaccine · 2003 · 136 citations

Vaccinology, Vaccination, Cross-protection +13

Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009–2013

Ross Cameron, Kimberley Kavanagh, Jiafeng Pan et al. · Emerging infectious diseases · 2015 · 135 citations · Full text

Vaccine Research, Hpv Infection, Human Papillomavirus Prevalence +23

Vesicle Size Influences the Trafficking, Processing, and Presentation of Antigens in Lipid Vesicles

James M. Brewer, Kevin G. Pollock, Laurence Tetley et al. · The Journal of Immunology · 2004 · 131 citations